Comparative Safety and Pharmacokinetic Variability of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease: A Systematic Review
Journal of Pioneering Medical Sciences · 2026-06-05 · 15 (05) · 222-229
DOI: 10.47310/jpms2026150530 ↗At a glance
Systematische Übersicht in Journal of Pioneering Medical Sciences, published online on 2026-06-05. Written by Moamen Abdelfadil Ismail and 12 co-authors.
Abstract (original language)
Background
Anticoagulation therapy becomes more challenging in patients with chronic kidney disease (CKD) due to the increased risk of thromboembolic and bleeding events. While DOACs have several benefits over more conventional treatments, there is still much we don't know about their pharmacokinetics and safety in CKD.
Objective
In order to conduct a comprehensive analysis of the relative safety and pharmacokinetic variability of DOACs in CKD patients.
Methods
In accordance with PRISMA 2020 standards, a systematic review was carried out. Up to December 2025, electronic databases were combed through. We considered studies that looked at the pharmacokinetics, bleeding risk, and thromboembolic outcomes of DOACs in CKD. Eleven research, comprising pharmacokinetic studies, randomized trials, and cohort studies, fulfilled the inclusion criteria.
Results
Significant pharmacokinetic variability was observed across DOACs. Dabigatran showed high renal dependence and increased accumulation risk in advanced CKD, while apixaban demonstrated stable pharmacokinetics and minimal dialyzability. Rivaroxaban exhibited intermediate characteristics. In hemodialysis populations, dabigatran and rivaroxaban were related to higher rates of bleeding, but apixaban consistently linked with a decreased major bleeding risk than warfarin. Evidence regarding thromboembolic outcomes was mixed, with some studies showing no significant benefit of anticoagulation in dialysis patients.
Conclusion
DOACs demonstrate variable safety and pharmacokinetic profiles in CKD. Apixaban appears to offer the most favorable balance between efficacy and safety, while dabigatran should be avoided in advanced CKD. Individualized treatment decisions are essential, and to determine the best anticoagulation therapies for this group, further randomized trials are required.
Cite
APA
Ismail, M. A., Hakami, A. A., Almenayan, B. A., Asiri, M. A., Aljawi, O. A., Alzahrani, R. A., Almalki, L. M. S., Alhumaidi, N. T., Alatwi, A. E. A., Asiri, H. M. S., Asswini, S. A., Alsaedi, A., & Alshahrani, I. M. M. (2026). Comparative Safety and Pharmacokinetic Variability of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease: A Systematic Review. Journal of Pioneering Medical Sciences, 15(05), 222-229. https://doi.org/10.47310/jpms2026150530
Vancouver
Ismail MA, Hakami AA, Almenayan BA, Asiri MA, Aljawi OA, Alzahrani RA, et al. Comparative Safety and Pharmacokinetic Variability of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease: A Systematic Review. Journal of Pioneering Medical Sciences. 2026;15(05):222-229. doi:10.47310/jpms2026150530
BibTeX
@article{Ismail2026,
author = {Ismail, Moamen Abdelfadil and Hakami, Aisha Awaji and Almenayan, Batool A. and Asiri, Mohammed A. and Aljawi, Omar Abdulaziz and Alzahrani, Rasha Ahmed and Almalki, Lujain Mneef Salm and Alhumaidi, Nidaa Turki and Alatwi, Alyah Eid Ali and Asiri, Hassan Moraya Saeed and Asswini, Sara Ahmed and Alsaedi, Abdulrahman and Alshahrani, Ibrahim Mofareh M.},
title = {Comparative Safety and Pharmacokinetic Variability of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease: A Systematic Review},
journal = {Journal of Pioneering Medical Sciences},
year = {2026},
volume = {15},
number = {05},
pages = {222--229},
doi = {10.47310/jpms2026150530}
}
EUVIMED